Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. more
Time Frame | PHAT | Sector | S&P500 |
---|---|---|---|
1-Week Return | 3.58% | 2.44% | 2.58% |
1-Month Return | -9.7% | -4.49% | 0.09% |
3-Month Return | -54.55% | -8.82% | 4.76% |
6-Month Return | -20.74% | -4.46% | 9.89% |
1-Year Return | -11.96% | 3.16% | 26.47% |
3-Year Return | -59.5% | -0.83% | 25.98% |
5-Year Return | -78.5% | 35.65% | 86.34% |
10-Year Return | -67.07% | 101.94% | 189.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 682.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 8.00K | 300.00K | 521.00K | 620.00K | 167.00K | [{"date":"2019-12-31","value":1.29,"profit":true},{"date":"2020-12-31","value":48.39,"profit":true},{"date":"2021-12-31","value":84.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":26.94,"profit":true}] |
Gross Profit | (8.00K) | (300.00K) | (521.00K) | (620.00K) | 515.00K | [{"date":"2019-12-31","value":-1.55,"profit":false},{"date":"2020-12-31","value":-58.25,"profit":false},{"date":"2021-12-31","value":-101.17,"profit":false},{"date":"2022-12-31","value":-120.39,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | - | - | - | 75.51% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 106.22M | 125.67M | 135.08M | 172.44M | 167.83M | [{"date":"2019-12-31","value":61.6,"profit":true},{"date":"2020-12-31","value":72.87,"profit":true},{"date":"2021-12-31","value":78.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.32,"profit":true}] |
Operating Income | (106.22M) | (125.67M) | (135.08M) | (172.44M) | (167.31M) | [{"date":"2019-12-31","value":-10621500000,"profit":false},{"date":"2020-12-31","value":-12566500000,"profit":false},{"date":"2021-12-31","value":-13508000000,"profit":false},{"date":"2022-12-31","value":-17244000000,"profit":false},{"date":"2023-12-31","value":-16731200000,"profit":false}] |
Total Non-Operating Income/Expense | (152.00M) | (6.89M) | (15.55M) | (50.46M) | (68.37M) | [{"date":"2019-12-31","value":-15200400000,"profit":false},{"date":"2020-12-31","value":-689300000,"profit":false},{"date":"2021-12-31","value":-1555000000,"profit":false},{"date":"2022-12-31","value":-5045600000,"profit":false},{"date":"2023-12-31","value":-6837200000,"profit":false}] |
Pre-Tax Income | (255.13M) | (129.07M) | (143.88M) | (197.72M) | (201.59M) | [{"date":"2019-12-31","value":-25513100000,"profit":false},{"date":"2020-12-31","value":-12906800000,"profit":false},{"date":"2021-12-31","value":-14388300000,"profit":false},{"date":"2022-12-31","value":-19772300000,"profit":false},{"date":"2023-12-31","value":-20159200000,"profit":false}] |
Income Taxes | (45.39M) | 4.25M | 4.21M | 25.28M | 41.78M | [{"date":"2019-12-31","value":-108.63,"profit":false},{"date":"2020-12-31","value":10.17,"profit":true},{"date":"2021-12-31","value":10.08,"profit":true},{"date":"2022-12-31","value":60.51,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (209.74M) | (133.32M) | (148.09M) | (223.01M) | (243.37M) | [{"date":"2019-12-31","value":-20974400000,"profit":false},{"date":"2020-12-31","value":-13331800000,"profit":false},{"date":"2021-12-31","value":-14809400000,"profit":false},{"date":"2022-12-31","value":-22300600000,"profit":false},{"date":"2023-12-31","value":-24337200000,"profit":false}] |
Income From Continuous Operations | (255.13M) | (129.07M) | (143.88M) | (197.72M) | (201.59M) | [{"date":"2019-12-31","value":-25513100000,"profit":false},{"date":"2020-12-31","value":-12906800000,"profit":false},{"date":"2021-12-31","value":-14388300000,"profit":false},{"date":"2022-12-31","value":-19772300000,"profit":false},{"date":"2023-12-31","value":-20159200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (209.74M) | (133.32M) | (148.09M) | (223.01M) | (201.59M) | [{"date":"2019-12-31","value":-20974400000,"profit":false},{"date":"2020-12-31","value":-13331800000,"profit":false},{"date":"2021-12-31","value":-14809400000,"profit":false},{"date":"2022-12-31","value":-22300600000,"profit":false},{"date":"2023-12-31","value":-20159200000,"profit":false}] |
EPS (Diluted) | (13.27) | (3.86) | (3.89) | (5.05) | (3.88) | [{"date":"2019-12-31","value":-1327,"profit":false},{"date":"2020-12-31","value":-386,"profit":false},{"date":"2021-12-31","value":-389,"profit":false},{"date":"2022-12-31","value":-505,"profit":false},{"date":"2023-12-31","value":-388,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PHAT | |
---|---|
Cash Ratio | 5.13 |
Current Ratio | 5.73 |
Quick Ratio | 5.68 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PHAT | |
---|---|
ROA (LTM) | -57.67% |
ROE (LTM) | -3489.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PHAT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.48 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.48 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PHAT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 19.52 |
P/B | 25.37 |
Price/FCF | NM |
EV/R | 13.50 |
EV/Ebitda | NM |
Phathom Pharmaceuticals Inc (PHAT) share price today is $8.1
Yes, Indians can buy shares of Phathom Pharmaceuticals Inc (PHAT) on Vested. To buy Phathom Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PHAT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Phathom Pharmaceuticals Inc (PHAT) via the Vested app. You can start investing in Phathom Pharmaceuticals Inc (PHAT) with a minimum investment of $1.
You can invest in shares of Phathom Pharmaceuticals Inc (PHAT) via Vested in three simple steps:
The 52-week high price of Phathom Pharmaceuticals Inc (PHAT) is $19.71. The 52-week low price of Phathom Pharmaceuticals Inc (PHAT) is $6.07.
The price-to-earnings (P/E) ratio of Phathom Pharmaceuticals Inc (PHAT) is
The price-to-book (P/B) ratio of Phathom Pharmaceuticals Inc (PHAT) is 25.37
The dividend yield of Phathom Pharmaceuticals Inc (PHAT) is 0.00%
The market capitalization of Phathom Pharmaceuticals Inc (PHAT) is $520.35M
The stock symbol (or ticker) of Phathom Pharmaceuticals Inc is PHAT